Pharmaceutical

(Curcumin + doxorubicin) by Immix BioPharma for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

Dec 24, 2023 - 18:00
(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC).
Read the original article

Tags:

Previous Article

Mecbotamab vedotin by BioAtla for Breast Cancer: Likelihood of Approval

Next Article

(Curcumin + doxorubicin) by Immix BioPharma for Metastatic Colorectal Cancer: Li...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MHRA reveals new corporate plan to expedite drug regulatory journeys in UK

MHRA reveals new corporate plan to expedite drug regula...

Jul 5, 2023

STAT+: Merck CEO refused to testify in Senate because he’s not an expert in drug pricing, Bernie Sanders says

STAT+: Merck CEO refused to testify in Senate because h...

Jan 28, 2024

STAT+: AI health care companies say they’ll keep humans in the loop. But what does that actually mean?

STAT+: AI health care companies say they’ll keep humans...

Mar 13, 2024